IL113310A - Substituted N-heteroaroylguanidines a process for their preparation pharmaceutical compositions containing them and their use for preparing medicaments - Google Patents

Substituted N-heteroaroylguanidines a process for their preparation pharmaceutical compositions containing them and their use for preparing medicaments

Info

Publication number
IL113310A
IL113310A IL11331095A IL11331095A IL113310A IL 113310 A IL113310 A IL 113310A IL 11331095 A IL11331095 A IL 11331095A IL 11331095 A IL11331095 A IL 11331095A IL 113310 A IL113310 A IL 113310A
Authority
IL
Israel
Prior art keywords
alkyl
perfluoroalkyl
substd
opt
ome
Prior art date
Application number
IL11331095A
Other languages
English (en)
Other versions
IL113310A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL113310A0 publication Critical patent/IL113310A0/xx
Publication of IL113310A publication Critical patent/IL113310A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
IL11331095A 1994-04-11 1995-04-10 Substituted N-heteroaroylguanidines a process for their preparation pharmaceutical compositions containing them and their use for preparing medicaments IL113310A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4412334A DE4412334A1 (de) 1994-04-11 1994-04-11 Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (2)

Publication Number Publication Date
IL113310A0 IL113310A0 (en) 1995-07-31
IL113310A true IL113310A (en) 2000-06-29

Family

ID=6515052

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11331095A IL113310A (en) 1994-04-11 1995-04-10 Substituted N-heteroaroylguanidines a process for their preparation pharmaceutical compositions containing them and their use for preparing medicaments

Country Status (16)

Country Link
US (1) US5698581A (fr)
EP (1) EP0676395B1 (fr)
JP (1) JP4171078B2 (fr)
CN (1) CN1073988C (fr)
AT (1) ATE248817T1 (fr)
AU (1) AU683722B2 (fr)
CA (1) CA2146707C (fr)
DE (2) DE4412334A1 (fr)
ES (1) ES2206471T3 (fr)
FI (1) FI951681A (fr)
HU (1) HUT71616A (fr)
IL (1) IL113310A (fr)
NO (1) NO304426B1 (fr)
NZ (1) NZ270894A (fr)
TW (1) TW349941B (fr)
ZA (1) ZA952930B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
CA2195697A1 (fr) * 1996-02-02 1997-08-03 Masahumi Kitano Derives substitues de la guanidine, procede pour leur obtention et leurs utilisations pharmaceutiques
DE19605610A1 (de) * 1996-02-15 1997-08-21 Hoechst Ag Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6136984A (en) * 1996-04-22 2000-10-24 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes
JPH09291076A (ja) * 1996-04-24 1997-11-11 Sumitomo Pharmaceut Co Ltd 置換グアニジン誘導体およびその製法
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
BR9908332A (pt) * 1998-02-27 2000-11-07 Pfizer Prod Inc Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
ME00275B (fr) 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
ES2384160T3 (es) 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US8110587B2 (en) 2002-02-11 2012-02-07 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
US7196207B2 (en) * 2002-07-24 2007-03-27 Mitsui Chemicals, Inc. Method for producing 2-alkyl-3-aminothiophene derivative
JP2006509014A (ja) * 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド メラノコルチンレセプターの調節因子
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
AU2005245399A1 (en) * 2004-05-12 2005-12-01 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
WO2008054605A2 (fr) * 2006-10-06 2008-05-08 Merck & Co., Inc. Inhibiteurs de transcriptase inverse non nucléosidique
WO2011005660A1 (fr) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Analogues de tofa utile dans le traitement de troubles ou états dermatologiques
EP2602248A1 (fr) 2011-12-05 2013-06-12 University Of Leicester Nouveaux composés pyrroliques
RU2631011C1 (ru) * 2016-07-12 2017-09-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный технический университет" Устройство для получения направленной силы инерции

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053674B (it) * 1968-01-31 1981-10-10 Istituto Farmacobiologico Sero N amidino carbossiamidi ossazoliche ad azione natriuretica
DE1965267C3 (de) * 1968-12-29 1975-07-31 Dainippon Pharmaceutical Co., Ltd., Osaka (Japan) 4-Nitropyrrol-2-carbonsäurehydrazldderivate, Verfahren zu deren Herstellung und deren Verwendung
BE758762A (fr) * 1969-11-12 1971-04-16 Shionogi & Cy Ltd Derives de l'isoxazole et leur preparation
FR2073284B1 (fr) * 1969-12-23 1973-07-13 Ferlux
SU380651A1 (ru) * 1971-05-11 1973-05-15 вители Саратовский государственный университет имени Н. Г. Чернышевского , Саратовский государственный медицинский институт Способ получения гуанидидов фуранкарбоновых или тетрагидрофуранкарбоновых кислот
US4894376A (en) * 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
TW213903B (fr) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
ATE139526T1 (de) * 1992-02-15 1996-07-15 Hoechst Ag 3,5-substituierte benzoylguanidine, mit antiarrythmischer wirkung und inhibierender wirkung auf die proliferationen von zellen
ES2108144T3 (es) * 1992-02-15 1997-12-16 Hoechst Ag Benzoilguanidinas sustituidas en orto, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DE59304166D1 (de) * 1992-07-01 1996-11-21 Hoechst Ag 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
ATE198328T1 (de) * 1992-09-28 2001-01-15 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2h)-isochinoline, verfahren zu deren herstellung, diese enthaltende arzneimittel und ihre anwendung für die herstellung eines arzneimittels zur behandlung von herzinsuffizienzen
US5260091A (en) * 1992-10-21 1993-11-09 Interneuron Pharmaceuticals Inc. Salt taste enhancers
DE59306029D1 (de) * 1992-12-16 1997-05-07 Hoechst Ag 3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2121391A1 (fr) * 1993-04-28 1994-10-29 Atsuyuki Kojima Derives d'indoloylguanidine
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
DE4327244A1 (de) * 1993-08-13 1995-02-16 Hoechst Ag Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
TW415937B (en) * 1994-01-25 2000-12-21 Hoechst Ag Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
NO304426B1 (no) 1998-12-14
FI951681A0 (fi) 1995-04-07
ZA952930B (en) 1996-01-26
US5698581A (en) 1997-12-16
EP0676395A3 (fr) 1996-03-06
NO951405L (no) 1995-10-12
EP0676395A2 (fr) 1995-10-11
CA2146707A1 (fr) 1995-10-12
NO951405D0 (no) 1995-04-10
JP4171078B2 (ja) 2008-10-22
AU683722B2 (en) 1997-11-20
HUT71616A (en) 1996-01-29
EP0676395B1 (fr) 2003-09-03
CN1117044A (zh) 1996-02-21
DE4412334A1 (de) 1995-10-19
FI951681A (fi) 1995-10-12
HU9501035D0 (en) 1995-06-28
ES2206471T3 (es) 2004-05-16
IL113310A0 (en) 1995-07-31
CN1073988C (zh) 2001-10-31
DE59510782D1 (de) 2003-10-09
NZ270894A (en) 1997-09-22
CA2146707C (fr) 2008-10-21
AU1635495A (en) 1995-10-19
ATE248817T1 (de) 2003-09-15
JPH07291927A (ja) 1995-11-07
TW349941B (en) 1999-01-11

Similar Documents

Publication Publication Date Title
IL113310A (en) Substituted N-heteroaroylguanidines a process for their preparation pharmaceutical compositions containing them and their use for preparing medicaments
RU2005128551A (ru) Замещенные n-арилгетероциклы, способ их получения и их применение в качестве лекарственных средств
PE20040949A1 (es) DERIVADOS DE HEXAHIDRO-PIRAZINO [1,2-a] PIRIMIDIN-4,7-DIONA SUSTITUIDOS EN POSICION 3 POR NITROGENO Y PROCEDIMIENTO PARA LA PREPARACION DE LA COMPOSICION FARMACEUTICA
HUP0400684A2 (hu) 5-Hidroxitriptamin-6-ligandumként használható heterociklilindazol- és -azaindazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
IL63613A0 (en) Benzoxazine derivatives,their preparation and pharmaceutical compositions containing them
ATE166056T1 (de) Gallium iii komplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
AR059956A1 (es) Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen
NO964639D0 (no) Substituerte sulfonimidamider, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
EP0368420B1 (fr) Compositions orales
Baker et al. The in vitro inhibition of microbial growth and plaque formation by surfactant drugs
DK0700899T3 (da) Substituerede benzoylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller diagnostikum s
DK0623138T3 (da) Nye adenosinderivater, fremgangsmåder til deres fremstilling og farmaceutiske præparater med indhold deraf
DK163126C (da) 1-ethyl-1,4-dihydro-4-oxo-3-carboxy-quinolin- eller -(1,8-naphthyridin)-derivater, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende disse samt udgangsmateriale til brug ved fremgangsmaaden
DK0691342T3 (da) Hidtil ukendte benzopyranderivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende dem
EG20530A (en) Process for preparing of phenoxyphenyl cyclopentenyl hydroxyureas
ATE5145T1 (de) O-creatinolphosphatderivat mit therapeutischer wirkung, verfahren zu dessen herstellung und dessen pharmazeutische zusammensetzungen.
Howell et al. Effect of topically applied stannous chlorofluoride on the dental caries experience in children
GB1160640A (en) Stannous Phosphonates and their use in Oral Compositions for Caries Prophyaxis
KR890000904B1 (ko) 치약 조성물
US4992260A (en) Method of inhibiting the formation of plaque
US5100649A (en) Method of inhibiting the formation of plaque
Crossland et al. Caries Experience in Rats Following Tooth-Brushing with Halogenated Triazines
JPH10316548A (ja) 口腔用組成物
TH8615A (th) ส่วนประกอบสำหรับช่องปาก
JPH0818951B2 (ja) 〔ベンゾ−１，２，４−チアジアジン〕−１−ジオキシド誘導体溶解組成物

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees